Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab.

MLA

Nikolakis, Georgios, et al. “Case Report: PsAPSASH Syndrome: An Alternative Phenotype of Syndromic Hidradenitis Suppurativa Treated with the IL-17A Inhibitor Secukinumab.” F1000Research, vol. 10, May 2021, p. 381. EBSCOhost, https://doi.org/10.12688/f1000research.52100.2.

APA

Nikolakis, G., Kreibich, K., Vaiopoulos, A., Kaleta, K., Talas, J., Becker, M., & Zouboulis, C. C. (2021). Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. F1000Research, 10, 381. https://doi.org/10.12688/f1000research.52100.2

Chicago

Nikolakis, Georgios, Katja Kreibich, Aristeidis Vaiopoulos, Katarzyna Kaleta, Joud Talas, Markus Becker, and Christos C Zouboulis. 2021. “Case Report: PsAPSASH Syndrome: An Alternative Phenotype of Syndromic Hidradenitis Suppurativa Treated with the IL-17A Inhibitor Secukinumab.” F1000Research 10 (May): 381. doi:10.12688/f1000research.52100.2.